We've already covered the controversy over flibanserin's long journey to market in multiple [2] blog posts [3]. But Lori Brotto, Ph.D. provides a viewpoint we may not have considered. In an editorial [4] for the Archives of Sexual Behavior, Brotto considers the possibility that the emergence of flibanserin on the market may actually provide an opportunity for researchers to delve into the efficacy of a psychosocial approach for women presenting with certain forms of sexual dysfunction. It's an interesting angle I haven't seen elsewhere yet. You can read the whole thing here [4].